PURPOSE To determine the incidence of rebound macular edema after intravitreal bevacizumab in eyes with macular edema secondary to branch retinal vein occlusion and to identify the pretreatment factors that were significantly associated with the rebound. METHODS The changes in the foveal thickness after the intravitreal bevacizumab (1.25 mg/0.05 mL) were studied in 65 eyes of 65 patients with...

BACKGROUND To investigate the effects of dyslipidemia and statin therapy on progression of diabetic retinopathy and diabetic macular edema in patients with type 2 diabetes. METHODS The medical records of 110 patients with type 2 diabetes (70 statin users and 40 non-users) were retrospectively reviewed. The two outcome measures were progression of diabetic retinopathy by two or more steps on t...

Macular edema secondary to retinal vein occlusion is commonly being treated with off-label intravitreal bevacizumab with good outcomes. A significant reduction in macular edema and improvement in visual acuity is seen following such a treatment with no serious adverse effects. In the reported case, a full-thickness macular hole was noticed one month after intravitreal bevacizumab for macular ed...

purpose: one of the major causes of visual acuity loss in diabetic patients is diabetic macular edema (dme). best-corrected visual acuity and central macular thickness changes are considered as two main outcomes in diabetic macular patients. the goal of this study was to compare the effect of intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation...

diabetic retinopathy is the leading cause of blindness in the world. strict control of blood sugar, blood pressure, laser therapy, pharmacotherapy and vitrectomy are of among common diabetic retinopathy treatments. further studies to investigate the effect of protein kinase c inhibitors, angiotensin converting enzyme inhibitors, growth hormone and other proposed treatments for diabetic retinopa...

normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background : diabetic macular edema (dme) is the most common cause of reduced vision in diabetic patients. with regards to its prevalence and its severe morbidity, attention to new methods of treatment like anti-vascular endothelial growth factor (vegf) therapy is of great importance. therefore, this study aimed to evaluat...

Objective: Remote Ischemic Preconditioning (RIPC) as the transient ischemia and reperfusion of the arm is a promising method for protecting different tissue from future ischemia. These effects might be mediated through vascular and endothelial growth factor (VEGF) pathway. We investigated the influence of RIPC on diabetic macular edema (DME) as a chronic ischemic condition in patients who were ...

purpose: to evaluate the effects of posterior subtenon triamcinolone acetonide (ta) injection on clinical, angiographic, and optical coherence tomographic (oct) features in refractory diabetic macular edema (dme). method: in a randomized double-masked placebo-controlled clinical trial, 38 consecutive patients (64 eyes) with dme refractory to previous laser therapy or not suitable for such treat...

PURPOSE To assess the macular thickness changes after cataract surgery in diabetic patients using optical coherence tomography (OCT). METHODS We retrospectively reviewed the records of 104 diabetic patients who underwent cataract surgery. We examined the changes of macular thickness using OCT before cataract surgery and 1 week, 1-, 2- and 6-months after surgery. The central subfield mean thic...

PURPOSE To evaluate patients' self-recognition of reduced visual acuity due to recurring macular edema in retinal vein occlusion. METHODS A retrospective review of medical records of patients who were diagnosed with recurring macular edema secondary to retinal vein occlusion was performed. The proportion of patients who recognized reduced visual acuity due to the recurrence of macular edema a...